These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21937968)

  • 61. Pharmacological developments in the treatment of depression.
    Jones M; Jones A
    Nurs Stand; 2009 Apr 15-21; 23(32):40-7; quiz 50. PubMed ID: 19441626
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Kynurenine pathway (KP) inhibitors: Novel agents for the management of depression.
    Hazari N; Bhad R
    J Psychopharmacol; 2015 Oct; 29(10):1133-4. PubMed ID: 26253624
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antidepressant use among survivors of childhood, adolescent and young adult.
    Kawada T
    Pediatr Blood Cancer; 2014 May; 61(5):953. PubMed ID: 24749163
    [No Abstract]   [Full Text] [Related]  

  • 64. Antidepressant use among survivors of childhood, adolescent, and young adult cancer: letter to the editor response.
    Deyell RJ; Lorenzi M; Spinelli JJ; McBride ML
    Pediatr Blood Cancer; 2014 May; 61(5):954. PubMed ID: 24357155
    [No Abstract]   [Full Text] [Related]  

  • 65. The pharmacogenomics of depression.
    Licinio J; Wong ML
    Pharmacogenomics J; 2001; 1(3):175-7. PubMed ID: 11908753
    [No Abstract]   [Full Text] [Related]  

  • 66. Discovery and development of antidepressants: a perspective from a pharmaceutical discovery company.
    Scolnick EM
    Biol Psychiatry; 2002 Aug; 52(3):154-6. PubMed ID: 12182921
    [No Abstract]   [Full Text] [Related]  

  • 67. The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments.
    Lu DY; Lu TR; Zhu PP; Che JY
    Cent Nerv Syst Agents Med Chem; 2015; 16(1):12-8. PubMed ID: 25924829
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress.
    Iosifescu DV
    JAMA; 2022 Jul; 328(2):146-148. PubMed ID: 35819435
    [No Abstract]   [Full Text] [Related]  

  • 69. Evidence Weak for Antidepressant Use in Children and Adolescents.
    Nelson R
    Am J Nurs; 2016 Sep; 116(9):17. PubMed ID: 27560326
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Epigenetics hints at future antidepressant drug targets.
    Lavine G
    Am J Health Syst Pharm; 2008 Jun; 65(12):1108-9. PubMed ID: 18541675
    [No Abstract]   [Full Text] [Related]  

  • 71. Role of the placebo effect in evaluating antidepressant efficacy.
    Carls KA
    Am J Health Syst Pharm; 2004 May; 61(10):1059-63. PubMed ID: 15160783
    [No Abstract]   [Full Text] [Related]  

  • 72. Drugs to Treat Depression.
    J Psychosoc Nurs Ment Health Serv; 2020 Jul; 58(7):5-7. PubMed ID: 32602928
    [No Abstract]   [Full Text] [Related]  

  • 73. Antidepressant Pharmacogenetics.
    Singh AB; Bousman CA
    Am J Psychiatry; 2017 May; 174(5):417-418. PubMed ID: 28457163
    [No Abstract]   [Full Text] [Related]  

  • 74. Pharmacogenetics of antidepressants.
    Sjöqvist F
    Psychopharmacol Ser; 1989; 7():181-91. PubMed ID: 2687856
    [No Abstract]   [Full Text] [Related]  

  • 75. Invited Perspective on Pharmacogenetics in Late-Life Depression.
    Bigos KL
    Am J Geriatr Psychiatry; 2020 Jun; 28(6):630-632. PubMed ID: 32151554
    [No Abstract]   [Full Text] [Related]  

  • 76. Adolescent depression.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):1. PubMed ID: 22339609
    [No Abstract]   [Full Text] [Related]  

  • 77. Clinical Economics. Depression.
    Klemas N; Dowling R
    Med Econ; 2015 Jun; 92(11):18-9, 23. PubMed ID: 26298959
    [No Abstract]   [Full Text] [Related]  

  • 78. Pharmacogenetics and the pharmacological management of depression.
    Krauter RR; Cook SS
    Nurse Pract; 2011 Oct; 36(10):14-21; quiz 21-2. PubMed ID: 21937968
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 80. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.